Edurant Ped is a drug owned by Janssen Products Lp. It is protected by 2 US drug patents filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 23, 2037. Details of Edurant Ped's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US7125879 | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(3 months from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11065198 | Dispersible compositions |
Oct, 2037
(12 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Edurant Ped's patents.
Latest Legal Activities on Edurant Ped's Patents
Given below is the list of recent legal activities going on the following patents of Edurant Ped.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed Critical | 20 Jul, 2021 | US11065198 |
| Patent Issue Date Used in PTA Calculation Critical | 20 Jul, 2021 | US11065198 |
| Email Notification Critical | 01 Jul, 2021 | US11065198 |
| Issue Notification Mailed Critical | 30 Jun, 2021 | US11065198 |
| Dispatch to FDC | 17 Jun, 2021 | US11065198 |
| Application Is Considered Ready for Issue Critical | 16 Jun, 2021 | US11065198 |
| Issue Fee Payment Verified Critical | 15 Jun, 2021 | US11065198 |
| Issue Fee Payment Received Critical | 15 Jun, 2021 | US11065198 |
| Electronic Review Critical | 16 Mar, 2021 | US11065198 |
| Email Notification Critical | 16 Mar, 2021 | US11065198 |
Several oppositions have been filed on Edurant Ped's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Edurant Ped's generic, the next section provides detailed information on ongoing and past EP oppositions related to Edurant Ped patents.
Edurant Ped's Oppositions Filed in EPO
Edurant Ped has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 09, 2012, by Hamm, Volker. This opposition was filed on patent number EP05108086A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP04787096A | Jan, 2016 | Page White & Farrer Limited | Patent maintained as amended |
| EP05108086A | Feb, 2012 | Hamm, Volker | The patent has been limited |
US patents provide insights into the exclusivity only within the United States, but Edurant Ped is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Edurant Ped's family patents as well as insights into ongoing legal events on those patents.
Edurant Ped's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Edurant Ped's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 23, 2037 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Edurant Ped Generics:
There are no approved generic versions for Edurant Ped as of now.
Alternative Brands for Edurant Ped
There are several other brand drugs using the same active ingredient (Rilpivirine Hydrochloride) as Edurant Ped. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Gilead Sciences Inc |
| ||
| Janssen Prods |
| ||
| Viiv Hlthcare |
|
About Edurant Ped
Edurant Ped is a drug owned by Janssen Products Lp. Edurant Ped uses Rilpivirine Hydrochloride as an active ingredient. Edurant Ped was launched by Janssen Prods in 2024.
Approval Date:
Edurant Ped was approved by FDA for market use on 15 March, 2024.
Active Ingredient:
Edurant Ped uses Rilpivirine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Rilpivirine Hydrochloride ingredient
Dosage:
Edurant Ped is available in tablet, for suspension form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 2.5MG BASE | TABLET, FOR SUSPENSION | Discontinued | ORAL |